2012-10-01 14:42:08 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Zhejiang Hangzhou Xinfu Pharma Co., Ltd. and produced a Rating Update Report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering Zhejiang Hangzhou Xinfu Pharma Co., Ltd. (2019). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Zhejiang Hangzhou Xinfu Pharma Co., Ltd. investor.
Report Summary: Zhejiang Hangzhou Xinfu Pharma Co., Ltd. is a low quality company with a positive outlook. Zhejiang Hangzhou Xinfu Pharma Co., Ltd. has weak business growth and is run by inefficient management. The trend in Zhejiang Hangzhou Xinfu Pharma Co., Ltd. fair value exchange rate against its closest rated-competitor, China Animal Husbandry Industry Co., Ltd, has been stable over the past 2 weeks. When compared to its closest competitor, Zhejiang Hangzhou Xinfu Pharma Co., Ltd.
shows greater overvaluation and is equally likely to underperform the market.
The 3-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Zhejiang Hangzhou Xinfu Pharma Co., Ltd. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.